Schedule 13G ownership disclosure

Forte Biosciences Inc

Common Stock, $0.001 par value · CUSIP: 34962G208

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L P

    Shares: 338,860.00 · Class: 5.3%

  • BVF I GP LLC

    Shares: 338,860.00 · Class: 5.3%

  • BIOTECHNOLOGY VALUE FUND II LP

    Shares: 262,365.00 · Class: 4.1%

  • BVF II GP LLC

    Shares: 262,365.00 · Class: 4.1%

  • Biotechnology Value Trading Fund OS LP

    Shares: 30,882.00 · Class: 0.5%

  • BVF Partners OS Ltd.

    Shares: 30,882.00 · Class: 0.5%

  • BVF GP HOLDINGS LLC

    Shares: 601,225.00 · Class: 9.3%

  • BVF PARTNERS L P/IL

    Shares: 643,622.00 · Class: 9.99%

  • BVF INC/IL

    Shares: 643,622.00 · Class: 9.99%

  • LAMPERT MARK N

    Shares: 643,622.00 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-000479
Form type
SCHEDULE 13G/A
Filer
BIOTECHNOLOGY VALUE FUND L P
CIK
CIK 918923
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub